Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
4.760
-0.240 (-4.80%)
Aug 14, 2025, 11:32 AM - Market open

Corvus Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-45.14-62.29-27.03-41.31-43.24-6
Upgrade
Depreciation & Amortization
0.090.090.150.370.460.63
Upgrade
Loss (Gain) From Sale of Assets
-0.01-0.01--0.02--37.46
Upgrade
Loss (Gain) From Sale of Investments
-1.39-1.14-0.89-0.170.240.15
Upgrade
Loss (Gain) on Equity Investments
3.783.25.2810.014.830.23
Upgrade
Stock-Based Compensation
4.0532.152.694.235.75
Upgrade
Other Operating Activities
8.0533.38----
Upgrade
Change in Accounts Receivable
-0.05-0.050.56-0.08-0.51-
Upgrade
Change in Accounts Payable
1.921.06-0.450.41-1.91.02
Upgrade
Change in Other Net Operating Assets
-0.15-2.66-3.711.08-0.830.89
Upgrade
Operating Cash Flow
-28.83-25.42-23.94-27.02-36.72-34.78
Upgrade
Capital Expenditures
-0.15--0.03-0.27-0.01-0.08
Upgrade
Sale of Property, Plant & Equipment
0.010.01-0.02--
Upgrade
Investment in Securities
-25.89-27.4915.58-23.0321.5744.85
Upgrade
Investing Cash Flow
-26.03-27.4815.54-23.2821.5644.77
Upgrade
Issuance of Common Stock
54.7135.067.86-62.161.31
Upgrade
Other Financing Activities
-13.97----
Upgrade
Financing Cash Flow
54.7149.037.86-62.161.31
Upgrade
Net Cash Flow
-0.15-3.88-0.54-50.34711.3
Upgrade
Free Cash Flow
-28.98-25.42-23.97-27.29-36.72-34.85
Upgrade
Free Cash Flow Per Share
-0.41-0.42-0.50-0.59-0.88-1.18
Upgrade
Levered Free Cash Flow
-23.0613.96-15.79-15.82-22.52-19.04
Upgrade
Unlevered Free Cash Flow
-23.0613.96-15.79-15.82-22.52-19.04
Upgrade
Change in Working Capital
1.72-1.65-3.591.41-3.241.91
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q